Overview
In March 2021 the Swiss Federal Council granted GARDP a privileged status, exonerating the organization from VAT as well as all direct and indirect taxes within Switzerland.
From an international perspective GARDP has a global presence in North America (GARDP NA, incorporated in May 2021) and South Africa (DNDi GARDP Southern Africa 2018). The accounts of both legal entities are consolidated into the combined financial statements. GARDP’s international presence is further enhanced through the DNDi offices located in East Africa, South-East Asia, Latin America, India and Japan.
Since its inception in 2016, GARDP has secured in excess of EUR 100M in funding. Despite the unpredictable nature of 2021, GARDP was able to successfully secure further funding from the UK, Japan and Switzerland (Canton de Genève and the Federal Office of Public Health) as well as the Leo Model Foundation. A further pledge for funding was also received from the Principality of Monaco.
To safeguard GARDP’s development in future, a diversified funding model of both restricted and unrestricted funding from both public and private sources will provide GARDP with the flexibility to manage its R&D activities into the long-term.
Numbers extracted from the unaudited “2021 Finance & Performance Report”. The full report, audited by Deloitte, will be available in June 2022 www.gardp.org
Income
In 2021 the UK’s Department of Health and Social care (DHSC) increased their financial support by contributing a further £4.5M and Switzerland (the Federal Office of Public Health) increased their funding by CHF 100k. The Leo Model Foundation continued its longstanding support with an additional $50k. New funding of $1.8M was received from a the Japanese Ministry of Health, Labour and Welfare, with a further pledge of $5.4M over the next three years as well as the Canton de Genève who have contributed CHF 540k. The Principality of Monaco pledged a further EUR 400k from 2022-24, and we received new funding of A$300k from the Australian government.
2021 Funding
EUR 17.3M
expenditure
Excluding the one-off early investment of EUR 8.9M in relation to cefepime-taniborbactam in 2020, total expenditure increased by EUR 2.6M or 18% in 2021. The growth of operational expenses reflects the increased activity within the Serious Bacterial Infections programme (in relation to cefepime-taniborbactam), the Sexually Transmitted Infections programme and the continued strengthening of the R&D structure along with and to a much lesser extent the set-up of GARDP North America Inc.
GARDP’s ratio of social mission to non-social mission spending dropped to 84% in 2021. This reduction was due to the continued impact of COVID-19 on some planned R&D operational activities.
2021 expenditure
EUR 17.4M
Funding commitments and pledges to date
EUR 104.7M:
PUBLIC CONTRIBUTORS FROM 2016 - 2025
EUR 101M
Germany (BMBF and BMG)
EUR 60.1M
UK (DFID, DHSC and NIHR)
EUR 21.7M
Japan (Ministry of Health, Labour and Welfare)
EUR 7.9M
The Netherlands (VWS)
EUR 7.5M
Switzerland (FOPH)
EUR 1.3M
South African Medical Research Council
EUR 0.9M
The Principality of Monaco
EUR 0.8M
Canton de Genève
EUR 0.5M
Australia (Department of Health)
EUR 0.2M
Grand Duchy of Luxemburg
EUR 0.1M
PRIVATE CONTRIBUTORS FROM 2016 - 2025
EUR 3.7M
Bill & Melinda Gates Foundation
EUR 1.8M
Wellcome Trust
EUR 1.1M
Others: Médecins Sans Frontières, Leo Model Foundation
EUR 0.8M
PartnerS
Collaborative investment to counter drug resistance
GARDP’s mission is to discover, develop, and deliver new antibiotic treatment options for drug-resistant infections that pose the greatest threat to health. This work could not be done without investment and support from our funding partners, each of whom understand the urgent need to address drug resistance. We would like to thank all of them.We would also like to acknowledge the ongoing recognition that the G7 and G20 give to AMR as a crucial global health issue (see 'Our Progress against Antibiotic Resistance').
In 2021, the Swiss government recognized our mission to develop new treatments for drug-resistant infections by granting a privileged status to GARDP.
2021 partnership and funding milestones
Partnerships with governments, academia, research centres, and industry are at the heart of GARDP’s work. Without the support of its partners, GARDP’s achievements to date would not have been possible.
GARDP is also collaborating with research centres on activities in the following countries:Bangladesh, Brazil, China, Greece, India, Italy, Kenya, the Netherlands, South Africa, Thailand, Vietnam, Uganda, and the United States.
January
Signed a Memorandum of Understanding (MOU) with the British Society for Antimicrobial Chemotherapy (BSAC) to collaborate on education, policy, and advocacy around antibiotic resistance.
February
The UK government announced £1.5 million of additional funding for GARDP to support the ongoing development of zoliflodacin, a potential new treatment for gonorrhoea.
March
The Swiss government recognized our mission to develop new treatments for drug-resistant infections by granting a privileged status to GARDP.
April
Signed a Declaration of Intent with the French Ministry for Europe and Foreign Affairs to explore opportunities for collaboration and strengthening activities to tackle antibiotic resistance.
May
Signed an MOU with the Indian Council of Medical Research (ICMR) to explore joint opportunities to tackle antibiotic resistance in India and globally.
Signed an MOU with the Indian Council of Medical Research (ICMR) to explore joint opportunities to tackle antibiotic resistance in India and globally.
June
The Japanese and British governments separately announced investments of ¥200 million and £1 million, respectively, in GARDP to support our work in tackling drug-resistant infections.
July
Signed an MOU with the Clinton Health Access Initiative (CHAI) and Shionogi & Co., Ltd to accelerate access to cefiderocol for bacterial infections in patients with limited treatment options, including in low- and middle-income countries (LMICs).
Initiated a partnership with German pharmaceutical company InfectoPharm to develop improved treatment options for neonatal sepsis using combinations of existing antibiotics.
September
Signed an MOU with the Department of Disease Control of the Thailand Ministry of Public Health (Thai DDC) to collaborate on an access and stewardship plan for zoliflodacin.
The Republic and Canton of Geneva announced funding of CHF 540,000 to support the development of zoliflodacin.
Partners Around the Globe
Partnerships with governments, academia, research centres, and industry are at the heart of GARDP’s work. Without the support of its partners, GARDP’s achievements to date would not have been possible.
GARDP is also collaborating with research centres on activities in the following countries:Bangladesh, Brazil, China, Greece, India, Italy, Kenya, the Netherlands, South Africa, Thailand, Vietnam, Uganda, and the United States.
R&D expenditure (EUR million)
Total GARDP expenditure since the start of its incubation within DNDi in 2016 totals EUR 76M
Actual expenditure 2016-2021 (EUR million)
Further information on GARDP’s income and expenditure will be available in GARDP’s 2021 Financial and Performance Report.
